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Abstract 
Purpose: Obesity is a risk factor for incident prostate cancer (PC) as well as risk 
of disease progression and mortality.  We hypothesized that men diagnosed with 
lower-risk PC and who elected active surveillance (AS) for their cancer 
management would likely initiate lifestyle changes that lead to weight loss.    
Methods and Patients: Patients were enrolled in the Prostate Active 
Surveillance Study (PASS), a multicenter prospective biomarker discovery and 
validation study of men who have chosen AS for their prostate cancer. Data from 
442 men diagnosed with PC within 1 year of study entry who completed a 
standard of care 12-month follow-up visit were analyzed.  We examined the 
change in weight and body mass index (BMI) over the first year of study 
participation. 
Results: After one year on AS, 7.5% (33/442) of patients had lost 5% or more of 
their on-study weight.  The proportion of men who lost 5% or more weight was 
similar across categories of baseline BMI: normal/underweight (8%), overweight 
(6%) and obese (10%, Chi-Square test p=0.44). The results were similar for 
patients enrolled in the study one year or six months after diagnosis.  By 
contrast, after one year, 7.7% (34/442) of patients had gained more than 5% of 
their weight. 
Conclusion: Only 7.5% of men with low-risk PC enrolled in AS lost a modest 
(≥5%) amount of weight after diagnosis. Given that obesity is related to PC 
progression and mortality, targeted lifestyle interventions may be effective at this 
‘teachable moment’, as men begin AS for low-risk PC. 
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Introduction 
 Obesity has been associated with increased risk of prostate cancer (PC) 
progression among patients managed with active surveillance (AS).1-6  Evidence 
from animal models suggests that weight loss may improve PC outcomes; 
however, this has not yet been demonstrated in human clinical trials.7,8 In 
addition to a potential reduction in PC progression as well as other morbidities 
with weight loss, weight reduction may reduce the risk of treatment-related 
complications (e.g., urinary incontinence) in those men who ultimately require 
treatment in subsequent years due to disease progression.3,9,10 
 Many patients demonstrate remarkable lifestyle modifications after a 
diagnosis of low-risk prostate cancer.11,12 These lifestyle changes include 
improved eating habits, increased daily physical activity, and weight loss. Few 
data exist on the effectiveness of these self-imposed lifestyle modifications that 
are done outside of formal programs. Population-based data suggest limited 
lifestyle modifications after diagnosis and potentially a reduction in exercise.13,14 
A diagnosis of cancer is thought to represent a teachable moment for 
patients, at which time patients would be more likely to adopt healthy lifestyle 
changes resulting in weight loss.   If these types of lifestyle changes are 
implemented, there may be an impact on cancer progression as well as a 
reduced risk of cardiovascular complications in the future.15 We sought to 
investigate whether a new cancer diagnosis without specific discussion of 
lifestyle changes led changes in body mass index utilizing the Canary Prostate 
Active Surveillance Study (PASS), a large, multi-institutional, prospective study of 
men with localized prostate cancer on active surveillance. 
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Methods 
 
PASS Study Population 
Data are from the Canary Prostate Cancer Active Surveillance Study 
(PASS), a multicenter, prospective study (clinicaltrials.gov NCT00756665) of 
men who elected AS for PC management.16,17 All men provided written informed 
consent prior to participation, and study procedures were approved by the local 
institutional review board for each study site. Men being seen in urology clinics 
were eligible for PASS if they had clinical stage T1-2 localized prostate cancer, 
no previous cancer treatment, no history of other malignancies (except non-
melanoma skin cancer), an Eastern Cooperative Oncology Group (ECOG) status 
of 0 or 1, and were willing to participate in a structured AS protocol including 
quarterly PSA measures, semi-annual digital rectal examinations, and periodic 
surveillance prostate biopsies.  There were no lifestyle or behavioral components 
as part of the protocol. The primary outcomes of PASS are the discovery and 
validation of biomarkers that predict outcomes to improve management of 
individual patients with prostate cancer. 
 
Data Collection, Definitions, and Outcomes 
At baseline, participants reported information on race/ethnicity, smoking 
status (never/former/current), alcohol use in the past year (one or more drinks 
per month), and family history of PC; clinic staff measured height and weight.  
Body mass index was calculated as weight (kg) divided by height (m2) and was 
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categorized as normal (BMI < 25), overweight (25 < BMI < 30), and obese (BMI > 
30).18 The primary outcome of this analysis was percentage weight change, 
calculated as the difference in weight between baseline and year 1 visits divided 
by weight at baseline visit.    
 
Statistical Analyses 
Weight loss of 5% or more, a level endorsed by the U.S. Centers for 
Disease Control and Prevention for improving cardiovascular health 
(http://www.cdc.gov/healthyweight/losing_weight/index.html), was of particular 
interest.18  Weight maintenance was defined as change in weight of ≤+/- 3% 
relative to baseline.  Minimal weight change was defined as +/-3.1%-4.9%, and 
modest weight change was defined as ≥+/- 5%, an amount considered clinically 
meaningful.  Weight change from baseline was compared across BMI categories 
using Fisher’s exact tests. Multiple linear regression models were used to 
evaluate the association of percentage weight change with demographic 
characteristics, including age (<55 (reference), 55-64 and 65+ years), race 
(Caucasian (reference), African-American, Other), BMI (normal (reference), 
overweight, obese), smoking status (current/former vs. never (reference), alcohol 
intake (<1 drink/month (reference) vs. 1+ drink/month) and family history of PC 
(no (reference) vs. yes). Study site was considered as a random effect in linear 
mixed models, but was found to neither improve model fit nor markedly change 
the fixed effect estimates and therefore was not included in final models.   Since 
the potential for weight change might be greatest among men with newly 
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diagnosed PC, data and analyses are presented separately for the subset of men 
who enrolled in PASS within 12 months or within 6 months of their PC diagnosis 
date. Statistical analyses were performed using SAS version 9.4 (SAS Institute, 
Inc., Cary, North Carolina).  All statistical hypotheses were 2 sided, and p < 0.05 
was considered statistically significant. 
 
Results 
 
Between September, 2008 and February, 2015, a total of 745 patients 
enrolled in PASS and had completed a 12-month follow-up visit.  Of these men, 
466 enrolled in PASS within one year, and 258 within 6 months, of PC diagnosis. 
Men enrolled later than 12-months from diagnosis or had missing data missing 
for any of the examined covariates were excluded, leaving 442 men for these 
analyses, 242 of whom were enrolled within 6 months of diagnosis. Demographic 
and health-related characteristics of study patients are displayed in Table 1. For 
the sample of patients enrolled within one year of cancer diagnosis, the mean 
age was 63 (SD=7), mean weight was 194 pounds (SD=32), and mean height 
was 70 inches (SD=3). Twenty-three percent (n=100) were normal, 52% (n=231) 
were overweight, and 25% (n=111) were obese. Overall, 7.5% (n=33) lost more 
5% or more of their body weight after 1 year. The distribution of demographic 
characteristics among the subset of patients enrolled within 6 months of their 
diagnosis was similar to the overall study sample. While men with a BMI < 25 lost 
on average 0.1 pounds (SD=4.0), overweight and obese men gained 0.4 
(SD=3.7) and 0.1 (SD=4.3) pounds, respectively, over the year after diagnosis. 
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Figure 1 shows the proportion of patients, for both the overall study 
sample and by BMI group, who lost, maintained, or gained weight during the first 
year of study enrollment after PC diagnosis. In the overall sample of patients 
enrolled within one year of cancer diagnosis (Figure 1A) and the subset of 
patients enrolled within 6 months of cancer diagnosis (Figure 1B), the majority of 
men maintained their enrollment weight (65% and 61%changed weight by ±3% 
or less, respectively). Among the overall sample of patients enrolled within 12 
months of PC diagnosis, similar proportions lost or gained more than 5% of their 
enrollment weight during the first year of study (7.5% and 7.7%, respectively; 
Figure 1A). A greater proportion of obese men had a weight loss of ≥5% 
compared to overweight or normal/underweight men (9.9% versus 6.1% and 
8.0%, respectively), and a similar pattern was seen for weight gain of ≥5% (9.9% 
versus 8.2% and 4.0%, respectively), although the differences in weight gain 
≥5% across baseline BMI categories was not statistically significant (Fisher’s 
exact test p-value=0.24).  
. Among the subset of 242 patients who enrolled within 6 months of PC 
diagnosis, a slightly greater proportion of men lost or gained ≥5% of enrollment 
weight, compared to men who enrolled within 12 months of PC diagnosis (9.1% 
vs. 7.5% with modest loss and 9.1% vs. 7.7% with modest gain, respectively). In 
addition, the proportions of obese, overweight and normal/underweight men who 
lost ≥5% weight were slightly greater among the subset of patients enrolled 
within 6 vs. 12 months of diagnosis (12.9% vs. 9.9% for obese, 7.1% vs. 6.1% for 
overweight and 9.4% vs. 8.0% for normal weight, respectively).   
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Among the 442 patients who enrolled within 1 year of diagnosis, none of 
the baseline variables significantly predicted weight change (Table 2).  In the 
subset of patients who enrolled within 6 months of diagnosis, men who had a 
family history of PC or did not regularly consume alcohol tended to lose more 
weight than men who did not have a family history of PC or were regular drinkers 
although these differences were neither clinically nor statistically significant 
(Table 2).  
 
Discussion 
In a sample of men with newly diagnosed, early stage PC enrolled in an 
AS study, of whom three-quarters were overweight or obese, we found little 
evidence to suggest that men made lifestyle changes that resulted in weight loss 
during the one-year period following enrollment in an AS study.  The majority of 
men (286/442, 65%) maintained their enrollment weight (≤±3%), and only 7.5% 
of men lost 5% weight or more during the first year of AS.  As troublesome, but 
perhaps not surprising, was the observation that a nearly equivalent number of 
men gained 5% or more from their enrollment weight (34/442, 7.7%) over the 
ensuing year.  
 These findings are consistent with those recently noted in a subset 
(n=511) of the Prostate testing for cancer and Treatment (PROTECT) trial in the 
United Kingdom in which no change in BMI after a diagnosis of PC was found.19  
No change in BMI was noted in this cohort despite approximately one-third of 
men modifying their behavior after their cancer diagnosis by reducing alcohol 
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intake, quitting smoking, or increasing physical activity without deliberate 
intervention.12,19 Men in the Prostate Cancer Prevention Trial (PCPT) overall only 
gained 1-2 1bs on average over the 7 years; however, the most at risk group for 
weight gain was men with low-grade cancer (71% higher annual weight gain than 
men with no cancer, p=0.002).20 This indicates men with a low grade prostate 
cancer diagnosis may actually be at risk for weight gain. Preliminary evidence 
suggests that small lifestyle modifications may make a difference in PC 
outcomes.  For instance, in the Health Professionals Follow-up Study, a modest 
amount of vigorous activity for ≥ 3 hours a week was associated with lower 
overall and PC-specific mortality.21 
 A diagnosis of PC, even when ‘low-risk’, can be a psychologically-
traumatizing event.22 We sought to determine whether men make lifestyle 
changes that would result in weight loss.  With the growing evidence that cancer-
specific survival for men with low-risk PC on AS is remarkably high (98% or 
more), we further wondered if behavioral change and weight loss could 
contribute to these outcomes. 3,23 
The majority of men in this large prospective PC AS study had either not 
changed, or increased, their weight within one year after diagnosis.  This striking 
observation supports the opportunity for a ‘teachable moment’ at the time of PC.  
Certainly, the simplest opportunity occurs if the patient decides to pursue a 
strategy of AS in which no other elements of his life change.  However, weight 
loss and dietary changes surrounding other prostate cancer therapies may also 
be beneficial.24  
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There is no single best method to achieve weight loss; however, elements 
that are important for clinical success mentioned by the National Heart, Lung, 
and Blood Institute (NIH) include setting goals that are specific, doable, and 
forgiving.25 They give an example of a goal that meets these requirements, such 
as “walk 30 minutes, 5 days each week” 
(https://www.nhlbi.nih.gov/health/educational/lose_wt/behavior.htm). This pointed 
information at the time of low-grade cancer diagnosis could be helpful to evoke 
behavioral change.  
Men on AS for PC have a very low disease-specific mortality rate, and 
instead have a higher risk of death from competing causes.  As a result, this 
moment is when the clinician can explain to the patient that lifestyle changes that 
reduce the risk of other causes of death (e.g., myocardial infarction, stroke, 
diabetes) would have a far-greater impact on health than interventions related to 
PC.26,27, 25, 13 This study and the PROTECT trial show that overweight or obese 
men on AS are unlikely to modify their lifestyle and lose weight.  Recently, the 
American Society of Clinical Oncology has established an initiative, which 
includes providing tools and resources for providers and patients regarding 
obesity including access to weight loss programs for cancer survivors.28  Formal 
programs to provide support should be a component of follow-up plans for men 
on AS.   
 Only 7.5% of men embarking in a program of active surveillance for low-
risk prostate cancer had a modest amount of weight loss of at least 5% reduction 
from baseline weight.  Physician facilitated multi-disciplinary weight loss 
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programs for all patients on surveillance for prostate cancer should be further 
investigated. 
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Figure 1: Change in weight during first year of enrolment in an active surveillance 
protocol. Results are shown for the total cohort and by BMI category, both for all 
participants enrolled in the study within one year of cancer diagnosis (A) and for those 
enrolled within 6 months of cancer diagnosis (B).  
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Table 1. Demographics of the study cohort. Results are shown for all 
participants diagnosed with prostate cancer within 1 year before study enrollment 
and a subset of those diagnosed within 6 months before enrollment. 
 
Demographics 
Diagnosed within 
1 year of 
enrollment 
Diagnosed within 
6 months of 
enrollment 
N(%) or mean (SD) N(%) or mean (SD) 
N=442 N=242 
Age (years) 63 (7) 634 (7) 
< 55 57 (13) 22 (9) 
55 ≤ Age < 65 182 (41) 106 (44) 
≥ 65 203 (46) 114 (47) 
Race   
Caucasian American 384 (87) 206 (85) 
Hispanic/Latino 20 (5) 12 (5) 
African American 19 (4) 10 (4) 
Asian 12 (3) 9 (4) 
Other 7 (1) 5 (2) 
Weight, baseline (pounds) 194 (32) 195 (32) 
Height, baseline (inches) 70 (3) 70 (3) 
Body Mass Index (kg/m2)   
<25 100 (23) 53 (22) 
25 ≤ BMI < 30 231 (52) 127 (52) 
≥ 30 111 (25) 62 (26) 
Lost 5% Body Weight 33 (7) 22 (9) 
Cigarette Use   
Current 17 (4) 7 (3) 
Former 172 (39) 101 (42) 
Never 253 (57) 134 (55) 
Alcohol Use (in past 12 mo.)  
Yes 370 (84) 198 (82) 
No 72 (16) 44 (18) 
Family History of PCa   
   Yes 111 (25) 65 (27) 
No 331 (75) 177 (73) 
 
 
Table 2. Association between weight change and patient characteristics. Weight change is recorded as Least Square (LS) means 
and standard errors (SE) from linear regression model.  
 
Diagnosed within 1 Year of enrollment 
(N = 442 ) 
Diagnosed within 6 Months of enrollment 
(N = 242) 
Baseline 
Demographics 
Mean 
Baseline 
Weight 
(lb) 
Weight change (lb) 
from baseline to 
year 1 
P-value*
Mean 
Baseline 
Weight 
(lb) 
Weight change (lb) 
from baseline to 
year 1 
P-value* 
Age      
< 55 194 0.26 (0.63)  190 -0.19 (1.02)  
55 ≤ Age < 65 200 0.26 (0.48) 0.59 200 -0.53 (0.72) 0.94 
≥ 65 189 -0.13 (0.46)  191 -0.53 (0.67)  
Race 
African American 197 0.62 (0.91) 202 -0.37 (1.39) 
Caucasian 194 -0.19 (0.31) 0.67 195 -0.32 (0.47) 0.97 
Other 192 -0.04 (0.67)  194 -0.55 (0.92)  
Body Mass Index     
Under / Normal 162 -0.40 (0.61)  162 -0.90 (0.90)  
Overweight 190 0.33 (0.49) 0.40 191 -0.75 (0.74) 0.41 
Obese 232 0.46 (0.61)  232 0.41 (0.90)  
Smoking Status     
Current / Former 197 0.29 (0.48) 
0.40 
199 -0.08 (0.73) 
0.24 
Never 192 -0.04 (0.45) 192 -0.74 (0.65) 
Alcohol intake (prior year)     
1+ drink per month 196 0.47 (0.40) 
0.18 
197 0.21 (0.60) 
0.09 
<1 per month 188 -0.21 (0.57) 186 -1.03 (0.84) 
Family history of PCa     
Yes 198 -0.07 (0.50) 
0.36 
198 -0.88 (0.76) 
0.13 
No 193 0.33 (0.45) 194 0.05 (0.65) 
* P-value from Type 3 Test, which tests the significance of each variable in the model, given all other variables in the model. Regression 
models are adjusted for baseline weight. 
 
